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Treatment-resistant depression (TRD) occurs in ~30% of patients with major depressive disorder 
(MDD) but the genetics of TRD was previously poorly investigated.  
Whole exome sequencing and genome-wide genotyping were available in 1209 MDD patients after 
quality control. Antidepressant response was compared to non-response to one treatment and non-
response to two or more treatments (TRD). Differences in the risk of carrying damaging variants were 
tested. A score expressing the burden of variants in genes and pathways was calculated weighting 
each variant for its functional (Eigen) score and frequency. Gene- and pathway-based scores were 
used to develop predictive models of TRD and non-response using gradient boosting in 70% of the 
sample (training) which were tested in the remaining 30% (testing), evaluating also the addition of 
clinical predictors. Independent replication was tested in STAR*D and GENDEP using exome array-
based data.  
TRD and non-responders did not show higher risk to carry damaging variants compared to responders. 
Genes/pathways associated with TRD included those modulating cell survival and proliferation, 
neurodegeneration and immune response. Genetic models showed significant prediction of TRD vs. 
response and they were improved by the addition of clinical predictors, but they were not significantly 
better than clinical predictors alone. Replication results were driven by clinical factors, except for a 
model developed in subjects treated with serotonergic antidepressants, which showed a clear 
improvement in prediction at the extremes of the genetic score distribution in STAR*D.      
These results suggested relevant biological mechanisms implicated in TRD and a new methodological 
approach to the prediction of TRD. 
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Major depressive disorder (MDD) is the second leading cause of disability in middle-aged adults on 
a global scale (1). Despite the availability of a number of different pharmacological treatments, 
treatment-resistant depression (TRD) is estimated to occur in ~30% of patients (2). TRD is usually 
defined as lack of response to at least two adequate treatments and it is associated with social and 
occupational impairment, suicidal thoughts, decline of physical health and increased health care 
utilization (3) (4). Annual costs for health care and lost productivity were estimated to be $5,481 and 
$4,048 higher, respectively, for a patient with TRD versus a patient with treatment-responsive 
depression (5).  
In the future, biomarkers associated with TRD risk may contribute to improve the clinical 
management of MDD by providing an estimate of TRD genetic risk at baseline, by guiding the 
prescription of personalized treatments and the development of new drugs. Genetic variants are ideal 
biomarkers to predict treatment response and TRD: a genetic basis to treatment response has been 
demonstrated and genotyping can be performed in easily accessible samples with reasonable cost and 
time (6). The development of models able to predict the genetic risk of TRD at baseline would provide 
valuable information to personalize treatment prescription and hypothetically reduce the rate of TRD. 
Possible ways by which this could be achieved include: 1) identifying genetic predictors of non-
response to specific antidepressant classes; 2) prescribing treatments with increased efficacy but 
limited availability because of costs constraints to patients having genetic risk for TRD. However, 
most existing pharmacogenomic studies were focused on measures of response to the last treatment 
without taking into account previous treatments, leaving the genetics of TRD largely unexplored (7). 
Another issue was the investigation of common variants only, while the possible role of rare variants 
was overlooked, despite they were suggested as one of the factors contributing to missing heritability 
of common traits (8). To the best of our knowledge, only a small pilot study (n=10) performed whole 
exome sequencing to the study of treatment response in MDD (but not TRD) and found that the bone 
morphogenetic protein (BMP5) gene may be associated with the therapeutic outcome (9).  
The present study aimed to contribute in filling the existing gap in the knowledge of TRD genetics 
using whole exome sequencing and genome-wide genotyping to analyze the role of rare and common 
variants in the prediction of this phenotype and contribute to the development of predictive models 






2. Patients and Methods 
2.1. Sample 
The Group for the Study of Resistant Depression (GSRD) sample was recruited within a multicenter, 
cross-sectional study including adult in- and outpatients with major depressive disorder (MDD) 
(DSM IV-TR criteria), as confirmed using the Mini International Neuropsychiatric Interview (MINI). 
Depressive symptom severity was assessed using the Montgomery and Åsberg Depression Rating 
Scale (MADRS) at study inclusion and at the onset of the current MDD episode. Information on 
previous and current antidepressant and other pharmacological treatments during the current MDD 
episode was collected as well as clinical-demographic characteristics. Antidepressant treatment was 
naturalistic according to best-clinical practice principles (Supplementary Table 1). The study protocol 
was approved by the local ethnic committees and the participant signed the written informed consent. 
Further details can be found elsewhere (10). 
  
2.2. Phenotype, training and testing samples 
TRD (treatment-resistant depression) was defined according to the most common definition of lack 
of response to at least two adequate antidepressant treatments during the current depressive episode 
(11), while non-response was referred to one adequate treatment only. Adequate treatment was 
defined as an antidepressant treatment of minimum duration of four weeks at least at the minimum 
therapeutic dose according to drug labeling. Response was defined as a MADRS score < 22 and a 
score decrease of at least 50% compared to the onset of the current MDD episode. Responders could 
have had not more than one failed antidepressant treatment during the current depressive episode. 
After quality control, the sample was split in a training (70%) and testing set (30%) which were 
balanced in terms of phenotypic distribution (TRD, non-response and response) using the partition 
function of groupdata2 R package, and they did not differ for gender, age, baseline depression severity 
or centre of recruitment. 
 
2.3. Whole exome sequencing and genome-wide genotyping  
Whole exome sequencing was performed using the Illumina HiSeq platform with 100 bp read length. 
Genome-wide genotyping was performed using the Illumina Infinium PsychArray 24 BeadChip 
(Illumina, Inc., San Diego) and these data were imputed as described in Supplementary Methods. 
Rare variants were extracted from exome sequence data and were defined as those having minor allele 
frequency (MAF) < 1/Ö(2n), where n is the sample size (12), which corresponded to 0.02 in GSRD. 
Information about DNA extraction, quality control of exome sequence data and genome-wide data 
are reported as Supplementary Methods. We compared the concordance of genotypes of SNPs 
	 5	
available in both exome sequence and array data, splitting them in genotyped and imputed and by 
minor allele frequency (MAF). These comparisons were also relevant to determine the putative 
reliability of rare imputed variants in the replication samples. Subjects with discrepancies between 
genome-wide and exome sequence data were excluded (non-major homozygote genotype 
concordance £ 90% for rare variants and £ 95% for common variants).  
 
2.4. Statistical analysis 
2.4.1. Variant annotation and distribution of functional variants  
We tested if predicted detrimental/damaging variants obtained through exome sequencing were 
differently distributed between TRD patients, non-responders and responders. Variant annotation was 
performed using Variant Effect Predictor (Vep) release 90, using the –pick flag that chooses one 
block of annotation per variant, based on an ordered set of criteria (13). Annotations from SIFT, 
PolyPhen and functional consequence scores from the Sequence Ontology (SO) project were used to 
estimate the relative pathogenicity of variants (14) (15) (17). The use of scores which combine 
different variant annotations was also pursued and it is described in the next paragraph. The risk of 
carrying SIFT deleterious variants (scores<0.05), PolyPhen damaging or probably damaging variants 
(scores>0.45) and variants with SO functional score ³ 0.90 and ³ 0.70 in specific genes was compared 
across TRD patients, non-responders and responders using regression models adjusted for three 
population principal components and center of recruitment. Bonferroni correction was applied to 
account for multiple testing (the number of included genes was between 14,353 and 18,600 depending 
from the considered annotation). Additional details are reported as Supplementary Methods.  
 
2.4.2. Exome risk scores   
These analyses aimed to estimate a weighted measure reflecting the burden of rare genetic variants 
exome-wide and in a gene- and pathway-based way. Secondly, we combined these measures with 
analogous estimations for common variants. 





where n is the number of genetic variants within the considered unit (whole exome, gene or pathway), 
vall is the number of alternative alleles, ws is the corresponding functional score and wf  is the frequency 
weight for that variant. In this way, the score is not dependent from the presence of individual variants 
which could not be observed in some of the tested samples. A similar approach was previously applied 
to the study of schizophrenia risk using exome sequence data (18), but it was modified in this study 
by using different functional weighting (composite scores reflecting multiple annotations) and 
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different frequency weighting (to allow the inclusion of rare but also common variants). Different 
sources for determining ws were tested and compared (Eigen scores (19), CADD scores (16) and SO 
functional scores (15), see Supplementary Methods). The frequency weight was determined using a 
beta distribution based on the frequency of the alternative allele alt_all (wf =dbeta(alt_all,1,25), 
according to the previous literature (12), see the corresponding curve in Supplementary Figure 1). 
Rare variants were extracted from exome sequence data as those with minor allele frequency (MAF 
< 1/Ö(2n), where n is the sample size (12), which corresponded to 0.02 in GSRD). Common intragenic 
variants were extracted from genome-wide genotyping data and clumped based on their functional 
scores ws and linkage disequilibrium (LD) using Plink v.1.9 (Supplementary Methods). A smoother 
beta distribution was used to weight these variants based on frequency (wf =dbeta(alt_all,0.5,0.5) (12), 
see curve in Supplementary Figure 1).  
The obtained scores were tested for different distribution among the phenotypic groups considering 
rare variants only and the sum of the scores for rare and common variants. These tests were performed 
using regression models adjusted for three population principal components and centre of recruitment. 
 
2.4.3. Predictive modeling 
Gene- and pathway-based scores (adjusted for the described confounders, more details in 
Supplementary Methods) were entered into a predictor selection process in the training sample using 
a five-fold cross-validation repeated 100 times for pathways and 20 times for genes, 500 and 100 
rounds in total, respectively. In each round, one fifth of the training dataset was left out, and in the 
remaining four-fifths of the training dataset a Correlation-Adjusted T (CAT) score was estimated (i.e. 
a multivariate generalization of the standard univariate T-test statistic that takes the correlation among 
variables explicitly into account (20) (21)) and the Local False Discovery Rate (LFDR) (i.e. the 
probability of a variable to be non-informative with regard to phenotype prediction given its CAT 
score) for each potential predictor. We selected predictors that had a LFDR smaller than 0.8 in > 50% 
of the rounds (22). This process reduces dimensionality and select variables with higher probability 
of being informative, reducing the risk of overfitting. These predictors were used to develop 
predictive models in the training sample using a gradient boosting machine (GBM) algorithm with a 
five-fold cross-validation repeated 100 and 20 times when predictors were pathway and gene scores, 
respectively. Cross-validation in this phase was used to provide better estimates of predictor 
contribution and empirically estimate model parameters (number of trees and interaction depth; 
shrinkage was set to 0.1 and minimum number of observations in each terminal node was set to 10). 
GBM produces a prediction model in the form of an ensemble of weak prediction models based on 
decision trees and it was demonstrated to be a suitable algorithm to learn from weak predictors, when 
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there is not a large amount of available data for training and predictors may interact among each other 
(23) (24). Models using gene-based scores as predictors included both rare and common variants, 
because the inclusion of rare variants only would have created scores very skewed towards zero which 
could not be realistically adjusted for confounders, while models using gene-set scores were tested 
for rare variants only and rare combined with common variants. 
The performance of the developed models in predicting TRD or non-response in the testing sample 
was estimated using the area under the curve (AUC) of ROC (receiver operating characteristic) curves. 
Predictive models were developed in the whole training sample and in the subsamples treated with 
serotonergic antidepressants (5-HT ADs) and noradrenergic or noradrenergic-serotonergic 
antidepressants (NA ADs) according to the pharmacology domain reported in the NbN classification 
(Neuroscience based Nomenclature) (25). Different genetic profiles were indeed previously found 
for antidepressants belonging to these pharmacology domains (22). Only the current treatment was 
considered and subjects treated with combinations of 5-HT ADs and NA ADs were not included in 
this analysis (Supplementary Table 1). The addition of a clinical risk score to the genetic predictors 
was evaluated. The clinical risk score was calculated as a weighted sum of the variables independently 
associated with TRD or non-response in the training sample in a regression model after Bonferroni 
correction (Supplementary Table 2). Each variable included in the clinical score was weighted for its 
effect size (z score) and divided by the number of variables available in each subject 
(∑ ./012345/	´	6/8)9:;<*=>?:+, ) in order to avoid the exclusion of subjects with one or two missing 
values. We compared the ROC curves including genetic predictors with those including clinical or 
clinical-genetic predictors using the DeLong’s method. 
The risk of TRD or non-response may increase particularly at the extremes of the genetic score 
distribution. Thus, we also tested the significant models including only subjects with a genetic score 
£ 30 or ³ 70 percentiles; we used this threshold to balance the risk of instability of findings due to 
the limited sample size, particularly in the subsamples treated with specific drug classes. The total 
genetic score was calculated in each subject as a sum of the gene/pathway scores included in the 
model of interest, each of them weighted for its importance in the predictive model. This approach is 
a simplification, since it does not reflect the non-linearity of the developed models and possible 
interactions.  
We did not perform multiple-testing correction for these analyses because: 1) these tests were 
correlated among each other and not independent (for example, patients in the tails of the genetic 
score are a subset); 2) we looked at the consistency of results of correlated analyses (i.e. we analysed 
patients in the tails or added the clinical score for further testing models which showed non-random 
prediction in the basic test). 
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The following R cran packages were used for the described analyses: caret, nnet, sda, crossval, pROC.   
 
2.5. Replication  
Replication of the significant predictive models was tested in STAR*D and GENDEP (26) (27), using 
the same approach described for creating gene- and pathway-based risk scores (including rare and 
common variants according to the definition reported in paragraph 2.4.2, more details are in 
Supplementary Methods). In replication samples we used a genetic score £ 20 or ³ 80 percentiles to 
identify subjects with extreme genetic scores since the larger sample size. In both these samples 
genome-wide genotyping was available, including standard genome-wide arrays and an exome array 
(Illumina Infinium Exome-24 v1.0 BeadChip) (28), but not exome sequence data. Further information 
on genotyping methods and quality control was previously reported (29) and it is described also in 
the Supplementary Methods. Imputation was carried out using the Michigan imputation server and 
the Haplotype Reference Consortium (HRC, version r1.1 2016) as reference panel (30). Different 
imputation quality thresholds were used to prune rare and common variants according to the previous 
literature (R2>0.30 and R2>0.60 for common and rare variants, respectively (31)(32)). The 
comparability between the available rare variants in GENDEP/STAR*D and GSRD was tested in 
terms of number and functional annotation. Phenotypes were defined in a way comparable to the 
GSRD sample, only TRD and response were considered because of their univocal phenotypic 
definition (part of non-responders are expected to become TRD) and these analyses aimed to replicate 
significant results in GSRD (which were concentrated to the comparison TRD vs. response). Further 
details on phenotype definition are reported in Supplementary Methods (paragraph “Replication 
samples: STAR*D and GENDEP”).  
 
2.6. Power estimation 
GSRD sample size after quality control (n=1209) provides adequate power (³0.80) in 865 out of 1000 
simulations when testing a set of 45 simulated rare variants (MAF < 0.02) and 100 simulated common 
variants (which reflects the median number of variants in the analysed genes), having effect sizes (b) 
randomly distributed between -0.25 and 0.25, at alpha=2.69e-06 (Bonferroni corrected p-value for 
number of genes). R cran libraries KATSP, minqa and CompQuadForm were used for power 
estimation (33).  
 
3. Results 
The number of subjects available after quality control was 1209 (details on number of excluded 
subjects are in Supplementary Figure 2). A comprehensive description of the clinical-demographic 
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characteristics of the samples is reported in Supplementary Table 1, while a condensed overview is 
shown in Table 1. The number of included variants split by variant type and MAF is reported in 
Supplementary Table 3 (exome sequence data). Five subjects showed low concordance between 
genotypes available in both exome and genome-wide data and they were excluded from the analyses 
including both rare and common variants, since exome sequencing repeated on one of these subjects 
demonstrated genotype concordance >99% with the initial sequencing results. The comparison 
between sequenced rare variants and rare variants imputed from genome-wide data showed a mean 
concordance of 75% (SD=5%) considering only non-major homozygote genotypes. The mean 
concordance considering the same comparison but for genotyped rare variants (array data) was 93% 
(SD=2%) (Supplementary Figure 3), suggesting that the use of rare variants obtained from an array 
may be feasible even though not optimal. From the genome-wide data, 476,319 intragenic common 
variants in low LD and 1180 subjects were included after quality control.  
The variables included in the clinical risk score were suicidal risk, number of previous depressive 
episodes, chronic depression and two MADRS factors (pessimism and interest-activity) 
(Supplementary Table 2).  
 
3.1. Distribution of damaging variants  
Patients with TRD and non-responders did not show an increased risk to carry SIFT/PolyPhen 
damaging variants compared to responders or variants with SO functional score ³ 0.90 or ³ 0.70 
(Supplementary Table 4 and Figure 1). When considering individual genes (Supplementary Tables 
5-6), we did not identify any difference among phenotypic groups after Bonferroni correction. The 
top gene was WDR90 (WD Repeat Domain 90) which showed variants with SO functional score ³ 
0.90 in 21 patients with TRD but only in 4 non-responders and 2 responders (p=3.44e-05).   
 
3.2. Exome-wide, gene and pathway scores 
The distribution of the of exome-wide scores for the three tested functional weights were substantially 
overlapping. Six patients were excluded from the subsequent analyses as they scored outside five 
standard deviations from the sample mean (Supplementary Figure 4). Patients with TRD and non-
responders did not show higher exome-wide scores compared to responders (p>0.05 for all three 
tested functional weights). The correlations between gene scores calculated using the three tested 
functional weights were high (mean correlation coefficient between 0.89 and 0.95 with SD from 0.04 
to 0.06 in pair-wise comparisons, Supplementary Figure 5). In consideration of these high correlation 
coefficients, the demonstration that Eigen scores have better discriminatory ability using disease-
associated and putatively benign variants from published studies compared to CADD scores (19), and 
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the lower functional precision of SO functional scores, only Eigen-based functional weighting was 
used in subsequent analysis.  
Gene- and pathway-based scores were not associated with phenotypic groups after Bonferroni 
correction (Supplementary Tables 7-8). The top genes were NBN and ZNF418 (p=4.34e-05 and 5.18e-
05, respectively, whole sample, Supplementary Table 4) and the top pathways were PID (protein 
interaction database) CD40 pathway in the subsample treated with serotonergic drugs and GO (gene 
ontology) response to cocaine in the subsample treated noradrenergic drugs (p=5.28e-05 and 5.61e-
05, respectively, Supplementary Table 8).  
 
3.3. Predictive modeling 
Pathway-based models for TRD vs. response in the whole sample including only rare genetic variants 
showed non-random prediction in the testing sample (n=237, AUC 0.61 [95% CI 0.54-0.69], Table 2 
and Figure 2) and in patients treated with 5-HT ADs (n=272 and n=118 in the training and testing 
samples respectively, AUC 0.62  [95% CI 0.52-0.73], Table 2 and Figure 2). The list of pathways 
used as predictors is in Supplementary Table 9 and their relative contribution to the models in 
Supplementary Figure 6. No significant prediction of TRD vs. response was observed in patients 
treated with NA ADs or when comparing non-responders vs. responders or TRD plus non-responders 
vs. responders (Supplementary Table 10). Prediction was improved by adding the clinical risk score 
to genetic predictors in both the whole sample and patients treated with 5-HT ADs (AUC 0.73 [0.66-
0.79] and AUC 0.65 [0.55-0.76], respectively, Table 2 and Figure 2), and this effect was more evident 
in subjects having extreme genetic scores for the included pathways (n=142, AUC 0.75 [0.67-0.83] 
and n=71, AUC 0.68 [ 0.55-0.82], respectively; Table 2 and Figure 2). However, there was no 
significant difference between the AUC obtained using the clinical risk score and that of the models 
including genetic and clinical predictors (p=0.89 and p=0.68 for the whole testing sample and for 5-
HT ADs, respectively). The clinical risk score showed similar or better AUC compared to the models 
including genetic predictors alone (p=0.03 and p=0.45 for the whole testing sample and for 5-HT 
ADs, respectively). A possible interpretation of this finding can be found in the observation that 
patients in the 5-HT ADs group had a lower clinical risk score compared to the others (p=9.73e-09).       
Pathway-based models including rare and common genetic variants did not show predictive effect in 
the testing sample in almost all scenarios (Supplementary Table 10).  
Gene-based models including rare and common variants predicted TRD vs. response in the whole 
testing sample and in subjects treated with 5-HT ADs (n=230, AUC 0.61, [0.53-0.69]; n=113, AUC 
0.65 [0.55-0.76], respectively; Table 2). The lists of genes used as predictors is shown in 
Supplementary Table 9 and their relative contribution to the models in Supplementary Figure 6. The 
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addition of the clinical risk score improved the prediction while the subgroups having scores in the 
extreme percentiles did not show different results (Table 2). There was no significant difference 
between the AUC of the model including only clinical predictors and that of the models including 
genetic and clinical predictors (p=0.74 and p=0.70 for the whole testing sample and for 5-HT ADs, 
respectively). The clinical risk score showed similar or better AUC compared to the models including 
genetic predictors alone (p=0.02 and p=0.50 for the whole testing sample and for 5-HT ADs, 
respectively).   
Predictive models of non-response vs. response showed marginal significance in the whole sample 
(n=211, AUC 0.59 [0.51-0.67]) but better values in the sample treated with 5-HT ADs (n=121, AUC 
0.64, [0.53-0.74]; Supplementary Table 10). However, given that models including non-responders 
were significant in a smaller number of scenarios compared to those focused on TRD, we did not 
further investigate them in the replication samples. 
 
3.5. Replication in STAR*D and GENDEP 
Despite the availability of genotypes from an exome array, a low covering of coding regions was 
obtained compared to exome sequence data, limiting the comparability of these data with those 
available in GSRD (Supplementary Figure 7). In GENDEP, LCE1B gene was not covered and we 
had to re-train the corresponding predictive model (gene scores in patients treated with 5-HT ADs) 
without this gene, with no major change in predictive performance in the GSRD testing sample (not 
shown). The number of included subjects and their main clinical-demographic characteristics are 
reported in Supplementary Table 11.  
None of the models including only genetic variables predicted TRD, apart from the rare variant 
pathway-based model developed in patients treated with 5-HT ADs. In STAR*D, this genetic model 
showed significant prediction of TRD risk in subjects with scores £ 10 or ³ 90 percentiles (we looked 
at more extreme percentiles because of the larger sample size; n=134, AUC 0.73, 95% CI 0.61-0.86, 
Table 3). The AUC of this model was not different from that of the model including clinical and 
genetic variables (p=0.63), but it was better compared to the model including clinical variables only 
(AUC of the clinical predictor: 0.55 [0.49-0.62], p=0.01). The other models showing replication (all 
including genetic and clinical predictors) are reported in Table 3; the ROC AUC of these models were 
not significantly different from those of the models based on the clinical risk score (all p > 0.05).  An 






This study found no overall difference in the distribution of functional and deleterious/damaging 
variants between TRD patients, non-responders and responders within the whole exome or within 
individual genes. The closest gene to the significance threshold was WDR90 (WD Repeat Domain 
90), which product function is still poorly known but it is thought to participate in microtubule 
organization within the presynaptic axon terminal (34). The tested risk scores were not associated 
with TRD at gene or gene set level, with NBN (nibrin) and ZNF418 (Zinc Finger Protein 418) genes, 
PID CD40 and GO response to cocaine pathways as top results. NBN is thought to be involved in 
DNA double-strand break repair, DNA damage-induced checkpoint activation and telomere integrity 
(35). It may be involved in neurodegenerative disorders (36). Variants in the ZNF418 region had a 
non-significant trend of association with MDD in a previous PGC (Psychiatric Genetic Consortium) 
mega-analysis (37) and in an exome sequence study (38). The PID CD40 gene set includes 31 genes, 
it is involved in the modulation of inflammation and CD40 ligand has been previously associated 
with MDD (39).  
The lack of strong signals coming from individual genes or pathways was expected as it is in line 
with a previous genome-wide association study of copy number variants (CNVs) that reported no 
significant enrichment of CNVs in TRD (40). Thus, it is reasonable to hypothesize that if genetics 
contributes to TRD, multiple genes/pathways must be involved with complex interactions. This 
mirrors the highly polygenic liability to MDD that is emerging from other studies (41). On the basis 
of this hypothesis, we applied predictive modeling to assess TRD risk using gene- and pathway 
genetic as well as clinical scores as predictors. Predictive modeling combining genetic and clinical 
predictors has been used by only two previous studies to predict antidepressant response to the best 
of our knowledge (22) (42), both these studies used SNPs from genome-wide genotyping as genetic 
predictors. In contrast to the present study, they did not perform any independent replication and the 
second study did not distinguish between training and testing sets (42).  
The present study applied an innovative approach which combined gene and pathway polymorphisms 
in genetic scores weighted by their functional relevance, using exome sequence and genome-wide 
data. The predictive models comparing TRD vs. response showed significant prediction in a higher 
number of scenarios compared to models including non-responders, confirming the biological 
relevance of TRD as a distinct phenotype. In this regard, it should be noted that non-responders are a 
more heterogeneous group than TRD patients, because part of them is expected to develop TRD. In 
the GSRD testing sample, both gene- and pathway-based models showed significant prediction of 
TRD vs. response (Table 2). The genes/pathways included in these models (Supplementary Table 9) 
are mostly involved in cell survival, cell growth and replication, cell migration, neurodegenerative 
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processes, neuroplasticity, immune system, hormonal regulation (sex and thyroid hormones) and 
second messenger cascades. Predictive performance was often improved by adding clinical risk 
factors and in the extreme percentiles of the score distribution. However, none of the genetic or 
genetic-clinical models showed a significantly better ROC AUC compared to the model including 
the clinical risk score only. We hypothesized two possible scenarios which could make the genetic 
predictors useful: 1) in patients with no clinical risk factors; 2) in patients having genetic scores at 
the extremes of the distribution. We preliminary tested the first hypothesis in GSRD whole testing 
sample: the pathway-based model showed AUC of 0.67 (0.54-0.81) in patients with no clinical risk 
factors (n=64) vs. AUC=0.61 (0.54-0.69) in the whole testing sample. The number of patients was 
limited (for this reason we did not explore this hypothesis in other subsamples), but the result supports 
the hypothesis that our genetic predictors perform slightly worse in patients with clinical risk factors, 
presumably because they are largely independent from them (i.e. genetic factors are not able to predict 
TRD cases caused by clinical variables having a distinct genetic or environmental basis). In line with 
this, there was no correlation between the cumulative genetic score (for any model) and the clinical 
risk score and genetic models were not able to predict TRD classification according to the clinical 
risk score. We hypothesized that the high impact of clinical risk factors in GSRD (most patients were 
complex cases of MDD, recruited in tertiary health care centres) may have led to a relative down-
weighting of genetic predictors in the clinical-genetic models (Supplementary Figure 6), explaining 
the fact that they did not show better performance in predicting TRD compared to the models 
including only the clinical risk score. We could not explore the contribution of the individual risk 
variables included in the risk score, because we used a cumulative score aimed to avoid the exclusion 
of subjects with partially missing data. 
The fact that genetic models developed in patients treated with 5-HT AD had better AUC point 
estimates (Table 2) may be explained by the fact that these patients had significantly lower clinical 
risk factors compared to the others (p=9.73e-09), since treatment prescription was naturalistic in 
GSRD. This means that the different gene/pathways selected in the whole sample compared to those 
selected in patients treated with 5-HT ADs may reflect their different clinical characteristics rather 
than differences due to distinctive biological mechanisms implicated in response to different drug 
classes. None of the analyses performed in the group treated with NA ADs was significant, a probable 
consequence of the small size of this group. In this regard, we also underline that polypharmacy was 
frequent in this sample, including combination and augmentation strategies (10), thus our 
classification according to the antidepressants pharmacology represented a simplified approach.  
The second scenario in which genetic predictors may be more relevant is in subjects with genetic risk 
scores at the extremes of the distribution. This case is exemplified by the clear improvement of 
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prediction in subjects with genetic scores £ 10 or ³ 90 percentiles in STAR*D (Table 3), the largest 
available sample in our study, which allowed to test more extreme percentiles compared to GSRD 
and GENDEP (at least the top 5% of the distribution was suggested to be meaningful for increased 
risk when using polygenic risk scores (43), but we had no power for this). The corresponding model 
was the only one showing replication of genetic predictors only and superiority over the clinical risk 
score, while prediction in other models showing replication in STAR*D or GENDEP was driven by 
the clinical score. Unfortunately, the genetic data available in the replication samples were poorly 
comparable with those available in GSRD (only arrays, with low coverage of coding regions) and 
there were also clinical differences between STAR*D, GENDEP and GSRD. For example, patients 
in STAR*D had very long depressive episodes of relatively mild severity, while in GENDEP there 
were no patients with chronic MDD according to the standard definition (>=2 years) and they had on 
average a lower number of previous episodes (Supplementary Table 11). Unlike the other samples, 
MADRS was not available in STAR*D and equivalent scores were calculated using the QIDS-C16 
scale (Supplementary Methods). The definition of the phenotype was performed slightly differently 
in each sample, because of the differences in study design. 
Bearing in mind the discussed limitations, our results contributed to clarify the genetic factors 
involved in TRD and it was the first study to assess the contribution of rare genetic variants through 
whole exome sequencing, if we exclude a very small pilot study performed on 10 subjects (9). No 
individual gene or pathway probably plays a major role in TRD, thus models including multiple 
genes/pathways and able to account for their interactions are probably the best strategy. Theoretically, 
pathway-based models are more suitable to take into account the complex genetic component of 
antidepressant response compared to gene-based models and they are expected to be more replicable, 
as confirmed by our top replication results. Our study represents a new approach to the prediction of 
treatment resistance in MDD and future improvements in larger samples may lead to clinical 
applications, at least in patients with extreme genetic scores or those with no clinical risk factors. In 
patients having genetic risk for TRD, treatment strategies with demonstrated higher efficacy (e.g. 
pharmacotherapy combined with psychotherapy (44)) but limited availability for cost constraints 
could be implemented as first line treatment, when these patients first seek treatment and there are 
still no clinical signs of severe MDD and no clinical risk factors for TRD, reducing the proportion of 
patients at risk who progresses towards resistance. 
	 15	
Acknowledgements 
We thank the NIMH for having had the possibility of analyzing their data on the STAR*D sample. 
We also thank the authors of previous publications in this dataset, and foremost, we thank the patients 
and their families who accepted to be enrolled in the study. Data and biomaterials were obtained from 
the limited access datasets distributed from the NIH-supported “Sequenced Treatment Alternatives 
to Relieve Depression” (STAR*D). The study was supported by NIMH Contract No. N01MH90003 
to the University of Texas Southwestern Medical Center. The ClinicalTrials.gov identifier is 
NCT00021528. 
The GENDEP project was supported by a European Commission Framework 6 grant (contract 
reference: LSHB-CT-2003-503428).  The Medical Research Council, United Kingdom, and 
GlaxoSmithKline (G0701420) provided support for genotyping.  This paper represents independent 
research part-funded by the National Institute for Health Research (NIHR) Biomedical Research 
Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views 
expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the 
Department of Health and Social Care. High performance computing facilities were funded with 
capital equipment grants from the GSTT Charity (TR130505) and Maudsley Charity (980).   
We thank Intomics (Copenhagen, Denmark) for genotype calling and contribution to quality control 
of exome sequence data in the GSRD sample.  
 
Conflict of interest 
Dr. Souery D. has received grant/research support from GlaxoSmithKline and Lundbeck; has served 
as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen and 
Lundbeck. Prof. Montgomery S. has been a consultant or served on Advisory boards: AstraZeneca, 
Bristol Myers Squibb, Forest, Johnson & Johnson, Leo, Lundbeck, Medelink, Neurim, Pierre Fabre, 
Richter. Prof. Kasper S. received grants/research support, consulting fees and/or honoraria within the 
last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-
Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, 
Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. Prof. Zohar J. has 
received grant/research support from Lundbeck, Servier, Brainsway and Pfizer, has served as a 
consultant or on advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion, AstraZeneca and Roche, 
and has served on speakers’ bureaus for Lundbeck, Roch, Lilly, Servier, Pfizer and Abbott. Prof. 
Mendlewicz J. is a member of the Board of the Lundbeck International Neuroscience Foundation and 
of Advisory Board of Servier. Prof. Serretti A. is or has been consultant/speaker for: Abbott, Abbvie, 
Angelini, Astra Zeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, 
	 16	
Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier. The other 
authors declare no conflict of interest. Cathryn Lewis is a member of the Scientific Advisory Board 
of Myriad Neurosciences   
 
Funding  
Chiara Fabbri is supported by a Marie Skłodowska-Curie Actions Individual Fellowship funded by 
the European Community (EC Grant agreement number: 793526; project title: Exome Sequencing in 
stages of Treatment Resistance to Antidepressants - ESTREA).  
Cathryn M. Lewis is part-funded by the National Institute for Health Research (NIHR) Biomedical 
Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. 
Dr Rudolf Uher is supported by the Canada Research Chairs Program. 
This study was supported by an unrestricted grant from Lundbeck for the Group for the Study of 
Resistant Depression (GSRD). Lundbeck had no further role in the study design, in the collection, 
analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper 
for publication. All authors were actively involved in the design of the study, the analytical method 
of the study, the selection and review of all scientific content. All authors had full editorial control 
during the writing of the manuscript and approved it. 
 
Data availability 
Genetic and clinical data from STAR*D study can be obtained by submitting an application at:  
https://www.nimhgenetics.org. Genetic and clinical data from GENDEP can be obtained by 
submitting an enquiry to cathryn.lewis@kcl.ac.uk. Genetic and clinical data from GSRD is available 
to analysts of the Psychiatric Genomics Consortium (https://www.med.unc.edu/pgc/), for enquires 
contact the corresponding author (alessandro.serretti@unibo.it).  
 
References 
1.  GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, 
and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 
1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016 
08;388(10053):1545–602.  
2.  Souery D, et al. Treatment resistant depression: methodological overview and operational 
criteria. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 1999;9(1–2):83–91.  
3.  Trivedi MH, et al. Evaluation of outcomes with citalopram for depression using 
measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 
2006;163(1):28–40.  
4.  Souery D, et al. Switching antidepressant class does not improve response or remission in 
treatment-resistant depression. J Clin Psychopharmacol. 2011;31(4):512–6.  
5.  Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and 
	 17	
societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv Wash DC. 
2014;65(8):977–87.  
6.  Tansey KE, et al. Contribution of Common Genetic Variants to Antidepressant Response. 
Biol Psychiatry. 2013;73(7):679–82.  
7.  Fabbri C, et al. The Genetics of Treatment-Resistant Depression: A Critical Review and 
Future Perspectives. Int J Neuropsychopharmacol. 2018;	22(2):93-104.  
8.  Gibson G. Rare and common variants: twenty arguments. Nat Rev Genet. 2012;13(2):135–
45.  
9.  Tammiste A, et al. Whole-exome sequencing identifies a polymorphism in the BMP5 gene 
associated with SSRI treatment response in major depression. J Psychopharmacol. 
2013;27(10):915–20.  
10.  Dold M, et al. Clinical correlates of augmentation/combination treatment strategies in major 
depressive disorder. Acta Psychiatr Scand. 2018;137(5):401–12.  
11.  Souery D, et al. Clinical factors associated with treatment resistance in major depressive 
disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–70.  
12.  Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests for 
the combined effect of rare and common variants. Am J Hum Genet. 2013;92(6):841–53.  
13.  McLaren W, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17(1):122.  
14.  Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on 
protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073–81.  
15.  Adzhubei IA, et al. A method and server for predicting damaging missense mutations. Nat 
Methods. 2010;7(4):248–9.  
16.  Kircher M, et al. A general framework for estimating the relative pathogenicity of human 
genetic variants. Nat Genet. 2014;46(3):310–5.  
17.  Koscielny G, et al. Open Targets: a platform for therapeutic target identification and 
validation. Nucleic Acids Res. 2017;45(D1):D985–94.  
18.  Curtis D. Construction of an Exome-Wide Risk Score for Schizophrenia Based on a 
Weighted Burden Test. Ann Hum Genet. 2018;82(1):11–22.  
19.  Ionita-Laza I, McCallum K, Xu B, Buxbaum JD. A spectral approach integrating functional 
genomic annotations for coding and noncoding variants. Nat Genet. 2016;48(2):214–20.  
20.  Zuber V, Strimmer K. Gene ranking and biomarker discovery under correlation. Bioinforma 
Oxf Engl. 2009;25(20):2700–7.  
21.  Zuber V, Strimmer K. High-dimensional regression and variable selection using CAR 
scores. Vol. Statistical Applications in Genetics and Molecular Biology. 2011.  
22.  Iniesta R, et al. Antidepressant drug-specific prediction of depression treatment outcomes 
from genetic and clinical variables. Sci Rep. 2018;8(1):5530.  
23.  Zhang Z, Zhao Y, Canes A, Steinberg D, Lyashevska O, written on behalf of AME Big-Data 
Clinical Trial Collaborative Group. Predictive analytics with gradient boosting in clinical medicine. 
Ann Transl Med. 2019;7(7):152.  
24.  Ogutu JO, Piepho H-P, Schulz-Streeck T. A comparison of random forests, boosting and 
support vector machines for genomic selection. BMC Proc. 2011;5 Suppl 3:S11.  
25.  Wilson S. Naming the drugs we use: neuroscience-based nomenclature, a helpful 
innovation. Ther Adv Psychopharmacol. 2018;8(6):171–2.  
26.  Rush AJ, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale 
and design. Control Clin Trials. 2004;25(1):119–42.  
27.  Uher R, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP 
project. Am J Psychiatry. 2010;167(5):555–64.  
28.  Fabbri C, et al. New insights into the pharmacogenomics of antidepressant response from 
the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. 
Pharmacogenomics J. 2018;18(3):413–21.  
29.  Fabbri C, et al. Genome-wide association study of treatment-resistance in depression and 
	 18	
meta-analysis of three independent samples. Br J Psychiatry. 2019;214(1):36–41.  
30.  Das S, et al. Next-generation genotype imputation service and methods. Nat Genet. 
2016;48(10):1284–7.  
31.  Sidore C, et al. Genome sequencing elucidates Sardinian genetic architecture and augments 
association analyses for lipid and blood inflammatory markers. Nat Genet. 2015;47(11):1272–81.  
32.  Pistis G, et al. Rare variant genotype imputation with thousands of study-specific whole-
genome sequences: implications for cost-effective study designs. Eur J Hum Genet. 
2015;23(7):975–83.  
33.  Wu B, Pankow JS. On Sample Size and Power Calculation for Variant Set-Based 
Association Tests. Ann Hum Genet. 2016;80(2):136–43.  
34.  Drew K, et al. Integration of over 9,000 mass spectrometry experiments builds a global map 
of human protein complexes. Mol Syst Biol. 2017;13(6):932.  
35.  Cilli D, et al. Identification of the interactors of human nibrin (NBN) and of its 26 kDa and 
70 kDa fragments arising from the NBN 657del5 founder mutation. PloS One. 2014;9(12):e114651.  
36.  Katsel P, Tan W, Fam P, Purohit DP, Haroutunian V. Cell cycle checkpoint abnormalities 
during dementia: A plausible association with the loss of protection against oxidative stress in 
Alzheimer’s disease [corrected]. PloS One. 2013;8(7):e68361.  
37.  Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, et al. A 
mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 
2013;18(4):497–511.  
38.  Subaran RL, Odgerel Z, Swaminathan R, Glatt CE, Weissman MM. Novel variants in 
ZNF34 and other brain-expressed transcription factors are shared among early-onset MDD 
relatives. Am J Med Genet Part B Neuropsychiatr Genet. 2016;171B(3):333–41.  
39.  Leo R, et al. Association between enhanced soluble CD40 ligand and proinflammatory and 
prothrombotic states in major depressive disorder: pilot observations on the effects of selective 
serotonin reuptake inhibitor therapy. J Clin Psychiatry. 2006;67(11):1760–6.  
40.  O’Dushlaine C, et al. Rare copy number variation in treatment-resistant major depressive 
disorder. Biol Psychiatry. 2014;76(7):536–41.  
41.  Howard DM, et al. Genome-wide meta-analysis of depression identifies 102 independent 
variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 
2019;22(3):343–52.  
42.  Lin E, et al. A Deep Learning Approach for Predicting Antidepressant Response in Major 
Depression Using Clinical and Genetic Biomarkers. Front Psychiatry. 2018;9:290.  
43.  Lewis CM, Vassos E. Prospects for using risk scores in polygenic medicine. Genome Med. 
2017;9(1):96.  
44.  Cuijpers P, et al. Adding psychotherapy to antidepressant medication in depression and 












Figure 1: representation of exome-wide distribution of variants with Sequence Ontology (SO) 
functional score ³ 0.90, SIFT deleterious variants, PolyPhen damaging/probably damaging variants. 
The examined phenotypic groups (x axis) were treatment-resistant depression (TRD), non-response 
























Figure 2: ROC curves of the non-random predictive models in GSRD testing sample and relative 
importance of the genetic predictors included in the models. When more than 20 predictors were 
included, only the first 20 are shown. 5-HT=serotonergic. The AUC values reached including only 
subjects with genetic scores £ 30 or ³ 70 percentiles. A. Genetic predictors only. B. Genetic and 















Table 1: main clinical-demographic characteristics of the training sample (n=847) and testing sample 
(n=362). The baseline MADRS score is referred to the beginning of the current depressive episode. 
MADRS=Montgomery and Åsberg Depression Rating Scale. TRD=treatment-resistant depression. 
Mean ± standard deviation is reported for continuous variables and distribution for dichotomous ones. 
For a more comprehensive overview of patients’ characteristics and results of comparisons between 
the characteristics of the two subsamples see Supplementary Table 1. 
Variable Training sample (n=847) Testing sample (n=362) 
Age 51.44±13.94 51.87±14.16 
Gender (F/M) 566/281 235/127 






Baseline MADRS score 34.56±7.36 33.85±7.69 
Current MADRS score  24.73±11.13 24.78±11.60 











Table 2: characteristics of the models showing significant prediction in the testing sample for the phenotype TRD vs. response. The results of the 
other tested models are shown in Supplementary Table 9. A. Pathway-based scores including rare variants; B. Gene-based scores including common 
and rare vairants. Sens=sensitivity; spec=specificity; PPV=positive predictive value; NPV=negative predictive value. 5-HT=serotonergic drugs. AUC 
95% confidence intervals are reported within parenthesis. * including only subjects with a genetic score £ 30 percentile or ³ 70 percentile see paragraph 
2.4.3 of the main manuscript for more details. 
A 
Subsample Genetic predictors only Genetic predictors + clinical 
risk score 
Extreme genetic percentiles*, 
genetic predictors only 
Extreme genetic percentiles*, 
genetic predictors + clinical score 
Whole 
testing set 
AUC 0.61 (0.54-0.69) 
Sens=0.42; spec=0.77; 
PPV=0.76; NPV=0.43 
AUC 0.73 (0.66-0.79) 
Sens=0.79; spec=0.57; 
PPV=0.76; NPV=0.60 
AUC 0.66 (0.56-0.75) 
Sens=0.53; spec=0.76; 
PPV=0.78; NPV=0.51 





AUC 0.62 (0.52-0.73) 
Sens=0.48; spec=0.77; 
PPV=0.76; NPV=0.49 
AUC 0.65 (0.55-0.76) 
Sens=0.73; spec=0.53; 
PPV=0.70; NPV=0.57 




Subsample Genetic predictors only Genetic predictors + clinical 
risk score 
Extreme genetic percentiles*, 
genetic predictors only 
Extreme genetic percentiles*, 
genetic predictors + clinical score 
Whole 
testing set 
AUC 0.61 (0.53-0.69) 
Sens=0.68; spec=0.55; 
PPV=0.72; NPV=0.49 
AUC 0.72 (0.65-0.79) 
Sens=0.67; spec=0.70; 
PPV=0.80; NPV=0.55 








AUC 0.65 (0.55-0.76) 
Sens=0.72; spec=0.59; 
PPV=0.72; NPV=0.59 
AUC 0.73 (0.63-0.83) 
Sens=0.72; spec=0.67; 
PPV=0.76; NPV=0.62 








Table 3: best predictive models of treatment-resistant depression (TRD) vs. response in the 
replication samples. For a detailed overview of all results in the replication samples see 
Supplementary Table 12. In STAR*D, more extreme percentiles of the genetic predictors were 
considered compared to other samples because of the larger sample size (for details see paragraph 




AUC (95% CI) 
Clinical and genetic predictors 









Genes, rare and 
common variants 
0.58 (0.49-0.68) 0.62 (0.53-0.72) 
STAR*D, whole 
sample (n=807)  
Genes, rare and 
common variants 
0.51 (0.46-0.55) 0.55 (0.51-0.59) 
STAR*D, 5-HT 
antidepressants, £ 20 




0.59 (0.48-0.69) 0.61 (0.51-0.71) 
STAR*D, 5-HT 
antidepressants, £ 10 




0.73 (0.61-0.86) 0.72 (0.58-0.86) 
 
 
